Quick Answer
Metagenomi Therapeutics, Inc. reported Revenue (ASC 606) of $25.21 million for fiscal year 2025.
Metagenomi Therapeutics, Inc. Revenue (ASC 606) — Annual History
| Fiscal Year | Revenue (ASC 606) | YoY Change |
|---|---|---|
| 2025 | $25.21M | -51.8% |
| 2024 | $52.30M | +16.8% |
| 2023 | $44.76M | — |
Quarterly Revenue (ASC 606)
| Quarter Ending | Revenue (ASC 606) | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $8.66M | -24.8% | +1.7% |
| June 30, 2025 | $8.51M | -57.5% | +106.3% |
| March 31, 2025 | $4.13M | -63.0% | -64.2% |
| September 30, 2024 | $11.51M | -6.9% | -42.5% |
| June 30, 2024 | $20.01M | +76.5% | +79.3% |
| March 31, 2024 | $11.16M | +28.9% | -9.7% |
| September 30, 2023 | $12.36M | — | +9.1% |
| June 30, 2023 | $11.34M | — | +31.0% |
- Metagenomi Therapeutics, Inc. showed a decrease of -51.8% in Revenue (ASC 606) compared to the prior fiscal year.
- Over the 2023–2025 period, Metagenomi Therapeutics, Inc.’s revenue (asc 606) has declined by 43.7% (from $44.76 million to $25.21 million).
- The most recent figure is from Metagenomi Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 5, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: